Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
plixorafenib (FORE-8394)
i
Other names:
FORE-8394, PLX 8394, PLX-8394, PLX8394, FORE8394, FORE 8394
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(20)
News
Trials
Company:
Daiichi Sankyo, Fore Biotherap
Drug class:
BRAF inhibitor, BRAF V600E inhibitor
Related drugs:
‹
vemurafenib (212)
dabrafenib (211)
PLX4720 (65)
avutometinib (27)
RAF265 (7)
ERAS-254 (7)
GDC 0879 (6)
RXDX-105 (5)
RAF709 (3)
HI-511 (1)
SB-590885 (1)
BGB-3245 (1)
PF-07284890 (1)
ARQ 736 (0)
ASN003 (0)
BDTX-4933 (0)
BMS-908662 (0)
RX208 (0)
PF-07799933 (0)
encorafenib (63)
ABM-1310 (5)
CB-006-3 (1)
vemurafenib (212)
dabrafenib (211)
PLX4720 (65)
avutometinib (27)
RAF265 (7)
ERAS-254 (7)
GDC 0879 (6)
RXDX-105 (5)
RAF709 (3)
HI-511 (1)
SB-590885 (1)
BGB-3245 (1)
PF-07284890 (1)
ARQ 736 (0)
ASN003 (0)
BDTX-4933 (0)
BMS-908662 (0)
RX208 (0)
PF-07799933 (0)
encorafenib (63)
ABM-1310 (5)
CB-006-3 (1)
›
Associations
(20)
News
Trials
VERI cancer hierarchy
Reset Filters
BRAF mutation
Ovarian Cancer
BRAF mutation
Ovarian Cancer
FORE-8394
Sensitive: C3 – Early Trials
FORE-8394
Sensitive
:
C3
FORE-8394
Sensitive: C3 – Early Trials
FORE-8394
Sensitive
:
C3
BRAF V600
Colorectal Cancer
BRAF V600
Colorectal Cancer
FORE-8394
Sensitive: C3 – Early Trials
FORE-8394
Sensitive
:
C3
FORE-8394
Sensitive: C3 – Early Trials
FORE-8394
Sensitive
:
C3
BRAF mutation
Melanoma
BRAF mutation
Melanoma
FORE-8394 + cobicistat
Sensitive: C3 – Early Trials
FORE-8394 + cobicistat
Sensitive
:
C3
FORE-8394 + cobicistat
Sensitive: C3 – Early Trials
FORE-8394 + cobicistat
Sensitive
:
C3
BRAF mutation
Colorectal Cancer
BRAF mutation
Colorectal Cancer
FORE-8394 + cobicistat
Sensitive: C3 – Early Trials
FORE-8394 + cobicistat
Sensitive
:
C3
FORE-8394 + cobicistat
Sensitive: C3 – Early Trials
FORE-8394 + cobicistat
Sensitive
:
C3
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
FORE-8394 + cobicistat
Sensitive: C3 – Early Trials
FORE-8394 + cobicistat
Sensitive
:
C3
FORE-8394 + cobicistat
Sensitive: C3 – Early Trials
FORE-8394 + cobicistat
Sensitive
:
C3
BRAF mutation
Thyroid Gland Papillary Carcinoma
BRAF mutation
Thyroid Gland Papillary Carcinoma
FORE-8394 + cobicistat
Sensitive: C3 – Early Trials
FORE-8394 + cobicistat
Sensitive
:
C3
FORE-8394 + cobicistat
Sensitive: C3 – Early Trials
FORE-8394 + cobicistat
Sensitive
:
C3
BRAF mutation
Glioma
BRAF mutation
Glioma
FORE-8394 + cobicistat
Sensitive: C3 – Early Trials
FORE-8394 + cobicistat
Sensitive
:
C3
FORE-8394 + cobicistat
Sensitive: C3 – Early Trials
FORE-8394 + cobicistat
Sensitive
:
C3
BRAF V600
Melanoma
BRAF V600
Melanoma
FORE-8394
Sensitive: C3 – Early Trials
FORE-8394
Sensitive
:
C3
FORE-8394
Sensitive: C3 – Early Trials
FORE-8394
Sensitive
:
C3
BRAF V600
Pancreatic Cancer
BRAF V600
Pancreatic Cancer
FORE-8394
Sensitive: C3 – Early Trials
FORE-8394
Sensitive
:
C3
FORE-8394
Sensitive: C3 – Early Trials
FORE-8394
Sensitive
:
C3
BRAF V600
Glioma
BRAF V600
Glioma
FORE-8394
Sensitive: C3 – Early Trials
FORE-8394
Sensitive
:
C3
FORE-8394
Sensitive: C3 – Early Trials
FORE-8394
Sensitive
:
C3
BRAF V600
Thyroid Gland Anaplastic Carcinoma
BRAF V600
Thyroid Gland Anaplastic Carcinoma
FORE-8394
Sensitive: C3 – Early Trials
FORE-8394
Sensitive
:
C3
FORE-8394
Sensitive: C3 – Early Trials
FORE-8394
Sensitive
:
C3
BRAF V600
Thyroid Gland Papillary Carcinoma
BRAF V600
Thyroid Gland Papillary Carcinoma
FORE-8394
Sensitive: C3 – Early Trials
FORE-8394
Sensitive
:
C3
FORE-8394
Sensitive: C3 – Early Trials
FORE-8394
Sensitive
:
C3
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.